BioCentury
ARTICLE | Top Story

Amgen prices Blincyto

December 18, 2014 2:27 AM UTC

Amgen Inc. (NASDAQ:AMGN) said it will launch leukemia drug Blincyto blinatumomab on Thursday with a price of $3,178.57 per single-use vial, or $89,000 for a 28-day treatment cycle.

Amgen spokesperson Lori Melancon said nearly all of the patients in a Phase II trial received two cycles of the drug, which would cost $178,000. Blincyto's label says patients could receive up to three additional cycles for consolidation treatment. ...